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ThE in vitro action of interferon (IFN)- and IFN-T from
six healthy donors and ten patients with multiple sclero-
sis (MS)on natural killer (INK) activity ofperipheral blood
lymphocytes (PBL) was studied in an autologous system.
The NK activity of PBL was detected by a cytotoxic test
using 3H-uridine human erythromyeloblast K562 cells.
Autologous IFN4x and IFN-T did not augment NK activity
ofPBL from healthy donors in vitro, whereas in samples
from MS patients the IFNs strongly stimulated NK cell
cytotoxic function. This stimulation suggests the exist-
ence of an inhibitor of regulatory IFN action, that is
produced in healthy donors simultaneously with IFN
in response to IFN induction, but which is lacking in
commercial IFN preparations. The factor-containing
supernatants from healthy donors reduced the
stimulatory action ofautologous IFNs in patients with MS
almost until complete blockade. Because this inhibitor
was absent in patients with MS, deficiency ofan inhibitor
of IFN regulatory action in MS could open the way to
treatment of this compartment of the immune system.
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Introduction
The ability of interferons (IFNs) to activate natural
killer (NK) cells is an important property of these
mediators. By inducing differentiation of pre-NK to
active NK forms, enhancing the lytic potency of a
single killer cell, and accelerating the recycling of NK’
cells after lytic interaction with their targets’,3 IFNs
serve factors playing a key role in the function of this
lymphocyte population. 1,"
The spectrum of immunomodulatory action
of IFNs, as well as their strong antiproliferative
activity, has led to the use of IFN preparations in
the therapy of oncological diseases. 5,6 However,
in spite of proven clinical efficiency, IFN action
does not correspond to expectation in patients
with idiopathic autoimmune haemolytic anaemia
in vitro, in a course of IFN therapy in chronic
granulocytic leukaemia or in myelodisplasia
patients.
Multiple sclerosis (MS) is a disorder where the
effects of IFN are puzzling.
1-1" If the use of IFN-ot and
IFN-[3 is characterized by a reduction in the number
11 12 and severity of exacerbations then IFN-,treatment
leads, at least in some patients, to exacerbation of the
pathological process,ha3 MS is associated not only
with a strong deficiency of cytotoxic NK cell activ-
ity1-7 and a functional defect of the IFN sys-
tem,5,6,18a9 but also anomalous responses ofNK cells
to regulatory IFN action. 14,7,’
NK cells produce multiple cytokines including
IFN, ,. and the reduced IFN production by peripheral
blood lymphocytes (PBL) possessing NK activity,5 in
1994 Rapid Communications of Oxford Ltd
patients with MS, is probably related to a defect in
monocyte helper."" There also appears to be a disso-
ciation between the cytotoxic and IFN-producing
activities of PBL exhibiting NK properties in this
disease,,. as well as maintenance of an excess of IFN
in the serum of blood and cerebrospinal fluid in
these patients. 9,’4 In the light of these relationships,
the aim of the present work was to study the
autologous (auto-) IFN-{z and IFN-7 actions on the
cytotoxic NK activity of PBL in patients with MS and
in healthy donors.
Materials and Methods
Six healthy donors (two men and four women)
aged between 18 and 48 years, and ten patients (four
men and six women) aged between 18 and 42 years
with evident MS
,.5 with remitting course of the pro-
cess at the stage of exacerbation, cerebrospinal form
and various duration of the disease (from 3 to 8
years), and IV-V degrees of invalidization (Kourtske
scale) were investigated.
Determination of the action of auto-IFN on NK
activity of PBL was carried out in two steps. Initially,
peripheral venous blood of patients was collected for
IFN induction while PBL were used to evaluate NK
cytotoxicity. Then, after IFN induction (on the 8th
day of investigation), PBL were isolated from periph-
eral blood of the same healthy donors and patients
with MS (MS patients received a placebo triaD, and
the action of auto-IFN on NK activity of these PBL
was determined.
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PBL were isolated from patients’ blood on
Ficoll-Paque (Pharmacia Fine Chemicals) gradients
of a density of 1.077 g/cm using the method of
B6yum. 26
The cytotoxic NK activity of PBL was measured by
the radiometric assay of Hashimoto and Sudo,27 as
modified by Rykova et al.,
28 using target cells of the
standard human erythromyeloblast line K562 la-
belled with H-uridine at a dose of 3 btCi/ml. PBL and
K562 cells were inoculated into the U-shape wells of
96-well microplates followed by co-incubation for
14 h at 37C in a humid atmosphere containing 5%
CO,.. The incubation was carried out in 0.2 ml RPMI-
1640 medium (Amimed) together with 12% v/v foetal
calf serum (NF Gamaleya Institute for Epidemiology
and Microbiology, Moscow), 10 mM HEPES (Serva),
2 mM glutamine, and 40 l.tg/ml gentamicin
(Pharmachim). NK activity was tested over a wide
range of effector:target cell (E:T) ratios 100:1, 50:1,
25:1, 12:1 and 6:1. Each E:T ratio was prepared in two
or three parallel wells. Initial suspensions of PBL
contained 10 PBL/ml, and the suspension of K562
targets contained 105 cells/ml. After stopping co-in-
cubation the PBL and K562 cells were harvested by
a 12-channel harvester (Dynatech) on glass fibre
filters with 2.5 l-tm pores (Whitman). Radioactivity
remaining on the filters was counted for 1 min for
each probe using I]-counters (Packard Mark II, USA).
The index of cytotoxicity (IC) was determined
according to the formula:
IC= (1_
cpm in testing well ) cpm in control well x 100%
Control wells contained K562 cells which were
labelled, prepared and incubated in the same manner
as those of test wells, but without PBL.
IFN- and IFN-,were induced in samples of whole
blood by Newcastle Disease Virus (Kansas strain) at
the dose of I CPU/ml and by phytohaemagglutinin P
(Difco) at the dose of 5 g/ml over 24 h at 37C in
an atmosphere of 5% COz using the method of
Kirchner et al.,z9 as modified by Grigoryan et al.
Inactivation of the inducing virus in IFN--containing
supernatants was achieved by adding 1N HC1 to
reduce the pH to 2.0. The mixture was incubated for
72 h at 4C then neutralized by adding 1N NaOH to
give a pH of 7.0. Titration of IFN was provided in M19
monolayer cultures of human fibroblasts according
1 h at 37C, then PBL washed free of IFN were
inoculated into wells of microplates. Because of the
lack of results for the induced IFN titration until the
second step of the investigation, the dosage of IFN
was controlled by adjusting the volume of added
supernatant.
Efficiency of IFN action was determined by regu-
latory parameters (RPs) presenting the ratios of abso-
lute changes of the IC to initial NK activities, counted
as mean values for all tested E:T ratios and expressed
with corresponding signs,
i Total RP (TRP) for a
group of observations was counted as mean value of
RPs in this group. Student’s t-test was used for evalu-
ation of the statistical significance of the results.
Results
The data in Fig. 1A show that auto-IFNs did not
augment the cytotoxic NK activity of PBL obtained
from blood of healthy donors. The TRP of auto-IFN-
was equal to -8_+16% and of auto-IFN-7 to
6 _+ 10%. At the same time auto-IFNs strongly acti-
vated PBL possessing NK activity in patients with MS
(Fig. 1B). The TRPs were 28 _+ 11% (p< 0.05) for
auto-IFN-0t and 56 + 26% (p < 0.05) for auto-IFN-,.
Comparison of the doses of auto-IFNs in the study
of IFN action on NK activity of PBL shows that the
same doses of auto-IFNs were used in normal
individuals as in MS patients (Table 1). Moreover,
these doses of auto-IFNs were similar to those
adopted in previous work concerning the regulatory
action of commercial IFN preparations on PBL NK
cytotoxicity,z where the difference was not more
than one dilution of IFN-containing supernatant.
1(6)
2 (6)
B
(0)
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to the method of Solovev and Bektemirov. 31 Vesicu- -4o
lar stomatitis virus (VSV) of Indiana strain was used
as a test virus. The reverse dilution of IFN which was
sufficient for a 50% protective effect of the IFN on
cells infected with 100 CPD50 was regarded as 1 unit
of the IFN titre.
To study IFN action on NK activity of PBL, 0.1 ml
of the IFN-containing supernatant was added to PBL
suspension (107 PBL/ml in 0.4 ml of the medium) for
-20 0 20 40 60 80 100
Total regulatory parameter (%)
Fig. 1. Action of auto-IFN-o (1) and auto-IFN-7 (2) in vitro on human NK
activity of PBL in healthy donors (A) and patients with MS (B). 107 PBL/ml
in a volume of 0.4 ml were treated with auto-IFN-x or auto-IFN-7 for h at
37C followed by washing free of IFNs and co-incubation with K562 targets
for 14 h at37C in humid atmosphere containing 5%CO2. Shading: p < 0.05
compared with TRP in healthy donors. The number of observations is
displayed in parentheses. One observation corresponds to RP counted for
one subject’s probe of PBL.
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Table 1. Doses of auto-IFNs used in the study of IFN action on PBL
NK activity
Donors Type of Dose of IFN Dose range
auto-IFN (lU/ml)* (lU/ml)
Healthy donors
MS patients
IFN-( 136.8 + 19.8 51.2 209.6
(n=6)
IFN-/ 32.2 + 8.4 12.8 112.2
(n=6)
IFN-( 164.2 + 24.1 46.8 409.6
(n=10
IFN-7 31.4 + 6.2 1.6 103.4
(n=9)
*Concentration of auto-IFNs in final PBL suspension is displayed.
Because of the lack of results for the auto-IFN titration until the
second step of the investigation, the dose of IFN was controlled by
adjusting the volume of supernatant added to PBL suspensions.
Thus, the described difference in properties of auto-
IFNs that stimulate NK activity of PBL in MS patients,
compared with those in healthy donors, was not
related to the other IFN doses used in the present
study.
The distribution of regulatory influences of auto-
IFNs on PBL NK activity was compared in MS patients
and in healthy donors. As can be seen from Table 2,
the number of observations when stimulation or
inhibition of NK activity of PBL, or absence of an
effect were seen, using all E:T ratios, were similar in
Table 2. Distribution of the in vitro effects of auto-IFNs on human
PBL NK activity (number of observations)*
Donors Type of Stimulation Absence Inhibition
IFN of NK of of NK
activity effects activity
Healthy IFN-( 8 (32)** 11 (44) 6 (24)
donors IFN- 10 (39) 10 (39) 6 (22)
MS patients IFN-( 13 (33) 14 (36) 12 (31)
IFN- 11 (37) 11 (37) 8 (26)
*One observation corresponds to the value of IC determined for
one definite E:T ratio in one subject. The summarized data for all
tested E:T ratios are presented.
**Number of observations in per cent is displayed in parentheses.
normal individuals and MS patients. Further, the
number of observations in which auto-IFNs did not
augment PBL NK cytotoxicity was equal to 68%
for IFN--0t and 67% for IFN-, in healthy donors, and
67% for IFN--0t and 63% for IFN-, in MS patients
(Table 2).
The modulatory action of auto-IFNs on PBL pos-
sessing NK cytotoxicity in MS patients was the same
as in healthy donors (Table 3), and these data may
indicate that the stimulatory effects of auto-IFNs
detected in MS patients were not related to changes
in the properties of these IFNs themselves or in the
sensitivity of the cells to regulatory IFN influence,
thus suggesting the existence and special role of
some additional factor controlling the regulatory
properties of IFNs.
Evaluation of NK activity of the blood cells ob-
tained from healthy donors and MS patients on the
1st and 8th days of study showed that NK activity of
PBL, expressed in both mean values of the IC and
comparison of the spectrum of its variability, did not
change over I week (Table 4). Thus, a change in NK
activity of PBL in analysing IFN regulatory action on
the cytotoxic function of the cells can be excluded.
Moreover, the data in the Table 4 show that PBL NK
activity in MS patients was lower than in healthy
donors but was sufficient for the evaluation of IFN
action, whether enhancing or reducing.
A possible influence of PHA, which may be
present in IFN-7-containing supernatants, could be
also excluded. Control tests were performed, includ-
ing a study of in vitro PHA P action on PBL NK
activity in three healthy subjects and four MS pa-
tients. PHA P was used at doses equal to those
inducing IFN-, or auto-IFN-7 production. PHA P did
not affect in vitro PBL NK cytotoxicity in either
healthy donors or MS patients (data not shown).
The IFN-containing supernatants obtained from
PBL of healthy donors, acting on IFN-enhanced NK
activity of MS patients’ PBL completely abolished the
stimulatory effect of auto-IFNs on PBL NK
cytotoxicity in MS patients (Fig. 2). The action of the
suggested inhibitor of IFN regulatory action on NK
Table 3. The relationship between initial NK cytotoxicity and the effects of auto-IFNs on PBL NK activity. Results
are given for MS patients and healthy donors
Initial
NK activity
of PBL
IFN- IFN-7
Stimulation Absence of Inhibition Stimulation Absence of Inhibition
an effect an effect
Healthy donors
High n 3
Normal n 2
Low n
MS Patients
High n 3
Normal n
Low n 6
2
2
2 2 -
3 2 5
(n is the number of observations)
Mediators of Inflammation. Vol 3. 1994 343S. B. Cheknev et al.
Table 4. Dynamics of NK activity of PBL on the 1st and 8th days of the study (IC in per cent, M _+ m)
E:T ratio
100:1 50:1 25:1 12:1 6:1
Healthy donors
(n=6)
1st day of study
8th day of study
MS patients
(n=O)
1st day of study
8th day of study
(after week placebo trial)
79.3 + 4.7 64.2 + 8.0 61.4 + 3.2 56.8 + 7.1 52.1 + 10.4
(70-82)* (48-81) (54-68) (47-76) (41-78)
79.3 + 9.1 64.7 + 5.9 60.3 + 5.7 54.2 + 5.2 50.1 + 15.0
(73-88) (53-77) (49-73) (36-74) (33-85)
58.1 + 5.0 67.2 + 3.4 40.0 + 7.2 33.3 + 3.8 29.7 + 8.1
(22-74) (57-76) (5-78) (1 6-54) (4-50)
52.3 + 8.8 54.8 + 8.7 52.0 + 6.1 32.4 + 7.7 27.1 + 6.0
(16-74) (12-84) (18-87) (16-61) (8-44)
*Range of the IC values is displayed in parentheses.
activity was evaluated by adding it, at doses corre-
sponding to those used for induced auto-IFNs, to a
PBL suspension stimulated with auto-IFN, and incu-
bating the mixture as described above for auto-IFNs.
After this procedure TRPs became equal to 6 + 5%
(p < 0.05) for IFN-- and to 9 + 7% (p < 0.05) for
IFN-y. The difference was statistically significant for
both these auto-IFNs (Fig. 2), and the values of TRPs
corresponded to those obtained for PBL from MS
patients possessing NK activity without any treat-
ment. This abolition of the IFN stimulatory effect on
PBL NK cytotoxicity by allogeneic factors was not
surprising because a negative regulation was found
to be efficient not only for autologous but also for
allogeneic systems in healthy donors (data not
shown).
1(10)
(10)
B
I.,. iii (9)
2 (9)
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Fig. 2. Blockade of stimulatory actions of auto-IFN-x (A) and auto-IFN-7 (B)
on NK activity of MS patients’ PBL by IFN-containing supernatants obtained
from PBL of healthy donors. The probes of IFN-containing supernatants
obtained from PBL of healthy donors in a volume of 0.1 ml were added to
PBL suspensions of MS patients simultaneously with 0.1 ml of auto-IFN-
containing probes for h at 37C followed by washing free of preparations
and measurement of PBL NK cytotoxicity (2). Shading: p < 0.05 compared
with TRP of auto-IFNs alone (1). The number of observations is displayed
in parentheses. One observation corresponds to RP counted for one
subject’s probe of PBL.
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Discussion
It has been shown in this study that non-purified
auto-IFN- and auto-IFN-7 did not stimulate NK ac-
tivity of PBL in healthy donors. This is a surprising
observation and contradicts those of Saksela et al.
and Targan and Dorey. However, in these earlier
studies a partially purified human leukocyte IFN was
used" and a commercial preparation of human
leukocyte IFN was applied, whereas we worked
with IFN preparations that had not been purified.
Additionally, we showed in earlier investigations that
commercial preparations of human leukocyte IFN, as
well as IFN-y at doses of 50 U/ml and 125 U/ml,
stimulated NK cytotoxic activity of PBL, with TRPs
equal to 270 + 106% and 143 _+ 61%, respectively, for
IFN-; and to a lesser extent, but also significantly,
with TRPs of 46 _+ 16% and 31 _+ 7.5%, respectively,
for IFN-7." The doses of IFNs used in this study were
similar to some used by Saksela et al.
At the same time as auto-IFN-, auto-IFN-7
strongly augmented NK activity of PBL obtained from
blood ofMS patients. Results from the control experi-
ments showed no change in either the
immunomodulatory properties of IFNs on PBL NK
activity, or the state of the PBL population possessing
NK activity. Additionally, in MS patients, there was
no change in the sensitivity of cells to the regulatory
effect of IFN, compared with similar effects in healthy
donors. Thus the present study seems to show the
first evidence of an inhibitor of IFN regulatory action
(IIRA) induced by IFN inducers and released simul-
taneously with IFN- and, more importantly, with
IFN-7. The nature of the lIRA remains unknown, but
as its production is associated with IFN induction,
and its blocking efficiency depends on the initial NK
activity of PBL, this factor might be one of a family
of IFN inhibitors described in previous studies.2,
The lack of IIRA in commercial IFN preparations adds
further weight to this suggestion. However, unlike
the Fleishmann et al.,2 or the Marchenko et al.,
factors, which abolished antiviral IFN effects, theAutologous enhancement by interferon
properties of our IIRA are expressed through a reduc-
tion in the efficiency of IFN-ot and IFN-7 stimulatory
influences on PBL possessing NK activity. On the
other hand, an inhibitor of the antiviral IFN action
contained in the ultrafiltrate of the culture fluid
obtained by induction of IFN on MCB murine cells
with NDV was concentrated after neutralization of
NDV in thin-channel wells of the TCF-10 apparatus,
and abolished the regulatory effect of IFN on the
sensitivity of murine L929 targets to a human NK cell-
mediated cytolysis. 34 At the same time, Cheknev et
aL34 also showed that incubation of the IFN-resistant
target cells of the MCB cell line led to an effect similar
to the well-known protective action of IFN itself. The
data obtained may therefore serve as a confirmation
of the existence of a family of IFN inhibitors, a part
of which is involved in regulation of NK cell activity
presumably when an excess of IFN appears in body
tissues and fluids.
It is interesting that the presence of the IIRA in IFN-
containing supernatants, and its ’antiregulatory’ ac-
tion on the properties of IFNs do not change the
antiviral activity of preparations, which can be evalu-
ated by a standard method that tests the protective
effect of IFN on monolayer human fibroblast cultures
infected with VSV. 31 These supernatant preparations
abolished the auto-IFN-induced stimulation of PBL
possessing NK activity in MS patients up to the values
of TRPs characteristic of the initial, untreated suspen-
sion of PBL. Thus, the blocking properties of the IIRA
can be exerted in both an autologous and an
allogeneic system.
MS represents a multifactorial immunological ab-
normality associated with a strong deficiency of NK
activity14-17 probably caused by a functional defect of
the IFN system.
18,35 This IFN-dependent NK defi-
ciency is linked with a reduction in IFN production
by practically all types of cells involved in the pro-
cess. 18’19’22 It is also associated with anomalous in
vitro responses of NK themselves as PBL possessing
NK activity to the IFN regulatory action, 14,17,2 and is
probably located at the stage of NK differentiation
controlled by IFN. An interleukin (IL)-dependent
step of maturation may also be involved, because IL-
2 was found to augment NK activity of PBL in MS
patients more slowly than in healthy donors, and
induced less IFN-,.6
On the other hand, some authors describe
activatory changes in MS patients. Maintenance
of excess IFN in serum and cerebrospinal fluid
of MS patients was reported by Degr et al. 24
and Hertzog et aL, 19 accompanied by dissociation
between the cytotoxic and IFN-producing functions
of PBL possessing NK activity.2 Furthermore, Salazar
et al.7 review properties of serum and tissue IFN-7
that induces demyelination in MS, while IFNs
produced in the central nervous system induce
remission.
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